379 results
DEFA14A
IMGN
Immunogen, Inc.
29 Jan 24
Additional proxy soliciting materials
5:01pm
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … , if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
No fee required
Fee paid previously with preliminary materials
Fee
8-K
IMGN
Immunogen, Inc.
29 Jan 24
Other Events
5:00pm
maintained by the SEC at www.sec.gov. ImmunoGen makes available free of charge on its investor relations website at www.immunogen.com copies of materials … in the Proxy Statement and may be set forth in other materials that may be filed with the SEC in connection with the proposed transaction when
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … , if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
No fee required
Fee paid previously with preliminary materials
Fee
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
on its investor relations website at www.immunogen.com copies of materials it files with, or furnishes to, the SEC.
The proposed transaction … , be different than those of ImmunoGen’s shareholders generally, are set forth in the Proxy Statement and may be set forth in other materials that may be filed
DEFA14A
IMGN
Immunogen, Inc.
8 Jan 24
Additional proxy soliciting materials
4:12pm
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … , if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
No fee required
Fee paid previously with preliminary materials
Fee
8-K
d3zn1g58
8 Jan 24
Other Events
4:11pm
DEFM14A
1zzhfw
2 Jan 24
Proxy related to merger
4:26pm
PREM14A
9bib0cr
21 Dec 23
Preliminary proxy related to merger
4:52pm
DEFA14A
5i6dbuu8fskr89
21 Dec 23
Additional proxy soliciting materials
3:54pm
DEFA14A
nd1wx81letc1z416
30 Nov 23
Additional proxy soliciting materials
4:08pm
DEFA14A
xdh1a
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
EX-99.1
5qm0eh cp
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
EX-2.1
ijltdo2z5e8 n9p
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
udfxyrf
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-2.1
7yykjft 2dc
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
89qmht
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-3.1
m4klylhxqy
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm